New strategies in hematopoietic stem cell transplantation: G-CSF-mobilized unprocessed whole blood

Detalhes bibliográficos
Autor(a) principal: Dräger,A.M.
Data de Publicação: 1998
Outros Autores: Ossenkoppele,G.J., Jonkhoff,A.R., Schuurhuis,G.J., Huijgens,P.C.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Medical and Biological Research
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X1998000100006
Resumo: Transplantation of mobilized peripheral blood stem cells (PBSC) for rescue of bone marrow function after high-dose chemo-/radiotherapy is widely used in hematologic malignancies and solid tumors. Mobilization of stem cells to the peripheral blood can be achieved by cytokine treatment of the patients. The main advantage of autologous PBSC transplantation over bone marrow transplantation is the faster recovery of neutrophil and platelet counts. The threshold number of PBSC required for adequate rescue of bone marrow is thought to be about 2 x 106 CD34+ cells/kg, if the stem cells are collected by leukapheresis and subsequently cryopreserved. We show that this critical number could be further reduced to as few as 0.2 x 106 cells/kg. In 30 patients with multiple myeloma and 25 patients with bad risk lymphoma 1 liter of granulocyte colony-stimulating factor (G-CSF)-mobilized unprocessed whole blood (stored at 4oC for 1-3 days) was used for transplantation. Compared to a historical control group, a significant reduction in the duration of neutropenia, thrombocytopenia and the length of hospital stay was documented. Furthermore, the effect of stem cell support was reflected by a lower need for platelet and red cell transfusions and a reduced antibiotic use. Considering the data as a whole, a cost saving of about 50% was achieved. To date, this easy to perform method of transplantation is only feasible following high-dose therapies that are completed within 72 h, since longer storage of unprocessed blood is accompanied by a substantial loss of progenitor cell function. Ongoing investigations include attempts to prolong storage times for whole blood
id ABDC-1_10161cb7277cc79c40811920207cfb1f
oai_identifier_str oai:scielo:S0100-879X1998000100006
network_acronym_str ABDC-1
network_name_str Brazilian Journal of Medical and Biological Research
repository_id_str
spelling New strategies in hematopoietic stem cell transplantation: G-CSF-mobilized unprocessed whole bloodhematopoietic stem cellstransplantationcytokinesG-CSFlymphomamultiple myelomaTransplantation of mobilized peripheral blood stem cells (PBSC) for rescue of bone marrow function after high-dose chemo-/radiotherapy is widely used in hematologic malignancies and solid tumors. Mobilization of stem cells to the peripheral blood can be achieved by cytokine treatment of the patients. The main advantage of autologous PBSC transplantation over bone marrow transplantation is the faster recovery of neutrophil and platelet counts. The threshold number of PBSC required for adequate rescue of bone marrow is thought to be about 2 x 106 CD34+ cells/kg, if the stem cells are collected by leukapheresis and subsequently cryopreserved. We show that this critical number could be further reduced to as few as 0.2 x 106 cells/kg. In 30 patients with multiple myeloma and 25 patients with bad risk lymphoma 1 liter of granulocyte colony-stimulating factor (G-CSF)-mobilized unprocessed whole blood (stored at 4oC for 1-3 days) was used for transplantation. Compared to a historical control group, a significant reduction in the duration of neutropenia, thrombocytopenia and the length of hospital stay was documented. Furthermore, the effect of stem cell support was reflected by a lower need for platelet and red cell transfusions and a reduced antibiotic use. Considering the data as a whole, a cost saving of about 50% was achieved. To date, this easy to perform method of transplantation is only feasible following high-dose therapies that are completed within 72 h, since longer storage of unprocessed blood is accompanied by a substantial loss of progenitor cell function. Ongoing investigations include attempts to prolong storage times for whole bloodAssociação Brasileira de Divulgação Científica1998-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X1998000100006Brazilian Journal of Medical and Biological Research v.31 n.1 1998reponame:Brazilian Journal of Medical and Biological Researchinstname:Associação Brasileira de Divulgação Científica (ABDC)instacron:ABDC10.1590/S0100-879X1998000100006info:eu-repo/semantics/openAccessDräger,A.M.Ossenkoppele,G.J.Jonkhoff,A.R.Schuurhuis,G.J.Huijgens,P.C.eng1998-10-07T00:00:00Zoai:scielo:S0100-879X1998000100006Revistahttps://www.bjournal.org/https://old.scielo.br/oai/scielo-oai.phpbjournal@terra.com.br||bjournal@terra.com.br1414-431X0100-879Xopendoar:1998-10-07T00:00Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)false
dc.title.none.fl_str_mv New strategies in hematopoietic stem cell transplantation: G-CSF-mobilized unprocessed whole blood
title New strategies in hematopoietic stem cell transplantation: G-CSF-mobilized unprocessed whole blood
spellingShingle New strategies in hematopoietic stem cell transplantation: G-CSF-mobilized unprocessed whole blood
Dräger,A.M.
hematopoietic stem cells
transplantation
cytokines
G-CSF
lymphoma
multiple myeloma
title_short New strategies in hematopoietic stem cell transplantation: G-CSF-mobilized unprocessed whole blood
title_full New strategies in hematopoietic stem cell transplantation: G-CSF-mobilized unprocessed whole blood
title_fullStr New strategies in hematopoietic stem cell transplantation: G-CSF-mobilized unprocessed whole blood
title_full_unstemmed New strategies in hematopoietic stem cell transplantation: G-CSF-mobilized unprocessed whole blood
title_sort New strategies in hematopoietic stem cell transplantation: G-CSF-mobilized unprocessed whole blood
author Dräger,A.M.
author_facet Dräger,A.M.
Ossenkoppele,G.J.
Jonkhoff,A.R.
Schuurhuis,G.J.
Huijgens,P.C.
author_role author
author2 Ossenkoppele,G.J.
Jonkhoff,A.R.
Schuurhuis,G.J.
Huijgens,P.C.
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Dräger,A.M.
Ossenkoppele,G.J.
Jonkhoff,A.R.
Schuurhuis,G.J.
Huijgens,P.C.
dc.subject.por.fl_str_mv hematopoietic stem cells
transplantation
cytokines
G-CSF
lymphoma
multiple myeloma
topic hematopoietic stem cells
transplantation
cytokines
G-CSF
lymphoma
multiple myeloma
description Transplantation of mobilized peripheral blood stem cells (PBSC) for rescue of bone marrow function after high-dose chemo-/radiotherapy is widely used in hematologic malignancies and solid tumors. Mobilization of stem cells to the peripheral blood can be achieved by cytokine treatment of the patients. The main advantage of autologous PBSC transplantation over bone marrow transplantation is the faster recovery of neutrophil and platelet counts. The threshold number of PBSC required for adequate rescue of bone marrow is thought to be about 2 x 106 CD34+ cells/kg, if the stem cells are collected by leukapheresis and subsequently cryopreserved. We show that this critical number could be further reduced to as few as 0.2 x 106 cells/kg. In 30 patients with multiple myeloma and 25 patients with bad risk lymphoma 1 liter of granulocyte colony-stimulating factor (G-CSF)-mobilized unprocessed whole blood (stored at 4oC for 1-3 days) was used for transplantation. Compared to a historical control group, a significant reduction in the duration of neutropenia, thrombocytopenia and the length of hospital stay was documented. Furthermore, the effect of stem cell support was reflected by a lower need for platelet and red cell transfusions and a reduced antibiotic use. Considering the data as a whole, a cost saving of about 50% was achieved. To date, this easy to perform method of transplantation is only feasible following high-dose therapies that are completed within 72 h, since longer storage of unprocessed blood is accompanied by a substantial loss of progenitor cell function. Ongoing investigations include attempts to prolong storage times for whole blood
publishDate 1998
dc.date.none.fl_str_mv 1998-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X1998000100006
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X1998000100006
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0100-879X1998000100006
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Divulgação Científica
publisher.none.fl_str_mv Associação Brasileira de Divulgação Científica
dc.source.none.fl_str_mv Brazilian Journal of Medical and Biological Research v.31 n.1 1998
reponame:Brazilian Journal of Medical and Biological Research
instname:Associação Brasileira de Divulgação Científica (ABDC)
instacron:ABDC
instname_str Associação Brasileira de Divulgação Científica (ABDC)
instacron_str ABDC
institution ABDC
reponame_str Brazilian Journal of Medical and Biological Research
collection Brazilian Journal of Medical and Biological Research
repository.name.fl_str_mv Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)
repository.mail.fl_str_mv bjournal@terra.com.br||bjournal@terra.com.br
_version_ 1754302928908189696